| Prev Close | 16.96 |
| Open | 16.96 |
| Day Low/High | 16.96 / 16.98 |
| 52 Wk Low/High | 3.02 / 17.05 |
| Volume | 8.44M |
| Avg Volume | 6.29M |
| Exchange | NASDAQ |
| Shares Outstanding | 193.76M |
| Market Cap | 3.29B |
| EPS | -0.31 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Updating a Small Speculative Play
Synergy Pharmaceuticals is developing drugs to treat gastrointestinal disorders and diseases. The
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Avanir Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...
Jim Cramer on the Stock Market: You Have to Love Biotech
In this era of turmoil, investors can take comfort in this sector.
Energy Stocks Shake Off Plunging Oil Prices to Push the Dow to New Highs
Oil prices backtrack from Monday's bounce, but energy stocks shake it off. Instead, the sector gains more than 1% after several weeks of punishing losses.
Stocks Hover Near Highs as Oil Backtracks From Monday Bounce
Oil is back in the spotlight Tuesday as prices backtrack from Monday's bounce and move lower again.
AVANIR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Otsuka Pharmaceutical Co., Ltd.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Avanir...
EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Avanir Pharmaceuticals Concerning Its Proposed Sale To Otsuka Pharmaceutical - AVNR
The Rosen Law Firm announces that it is investigating the Board of Directors of Avanir Pharmaceuticals, Inc.
Stocks Gain as Construction Spending Expands, Global Stimulus Talk Heats Up
U.S. stocks book modest gains on Tuesday morning as domestic construction spending expands.
AVNR INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Of The Board Of Directors Of Avanir Pharmaceuticals, Inc. In Connection With The Fairness Of The Sale Of The Company To Otsuka Pharmaceutical Co., Ltd. -- AVNR
Levi & Korsinsky is investigating the Board of Directors of Avanir Pharmaceuticals, Inc.
Avanir Fetches $3.5B From Japan's Otsuka for Reformulated Cough Syrup
The Japanese drugmaker is trying to shore up its product pipeline ahead of April 2015 when patents on its best-selling schizophrenia drug Abilify expire.
Stock Futures Rise as Wall Street Recovers From Tech, Retail Selloff
U.S. stock futures edge higher on Tuesday after a selloff among tech and retail names left all benchmark indices in the red a day earlier.
AVANIR Pharmaceuticals (AVNR) Is Today's Pre-Market Mover With Heavy Volume Stock
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a pre-market mover with heavy volume candidate
Avanir Pharmaceuticals (AVNR) Stock Surges Today on $3.54 Billion Otsuka Deal
Avanir Pharmaceuticals (AVNR) will be purchased by Otsuka Holdings Co. for about $3.54 billion, a deal that gives the Japanese company new treatments for neurological conditions,
December 2 Premarket Briefing: 10 Things You Should Know
U.S. stock futures rise slightly; Avanir to be bought by Japan's Otsuka Pharmaceutical; Cypress to buy Spansion; Ford and GM to report monthly sales.
Avanir Pharmaceuticals (AVNR) Stock Drops After FDA Provides New Drug Application Feedback
Shares of Avanir Pharmaceuticals (AVNR) fell after the FDA provided preliminary written feedback to the biopharmaceutical company regarding its New Drug Application (NDA) for its migraine treatment drug AVP-825.
Will Avanir Pharmaceuticals (AVNR) Stock React Today to This Analyst Action?
Deutsche Bank initiated coverage of Avanir Pharmaceuticals (AVNR) with a 'buy' rating and a price target of $17.
Perilous Reversal Stock: AVANIR Pharmaceuticals (AVNR)
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's Post-Market Leader Stock
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a post-market leader candidate
Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's Post-Market Leader Stock
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a post-market leader candidate
